# ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07452224/  
OnCo record `nct07452224` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by iLeukon Therapeutics, Inc., now recruiting.

## Summary

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07452224 by iLeukon Therapeutics, Inc., with 80 participants planned, started 2026-06-29 and due to reach its primary completion in 2029-06. Interventions recorded: ILKN421H, Pembrolizumab. Conditions listed: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07452224
- Phase: 2
- Setting: An Open-Label Phase II Study of ILKN421H in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: iLeukon Therapeutics, Inc.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07452224: https://clinicaltrials.gov/study/NCT07452224

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct07452224.json